- Report
- December 2022
- 122 Pages
North America
From €3132EUR$3,450USD£2,698GBP
- Report
- December 2022
- 137 Pages
Europe
From €3132EUR$3,450USD£2,698GBP
- Report
- August 2022
- 273 Pages
Europe
From €3132EUR$3,450USD£2,698GBP
- Report
- May 2022
- 347 Pages
Global
From €4039EUR$4,450USD£3,480GBP
- Report
- March 2026
- 381 Pages
China
From €4403EUR$4,850USD£3,793GBP
- Report
- March 2026
- 170 Pages
Germany
From €4403EUR$4,850USD£3,793GBP
- Report
- March 2026
- 342 Pages
Canada
From €4403EUR$4,850USD£3,793GBP
- Report
- March 2026
- 209 Pages
India
From €4403EUR$4,850USD£3,793GBP
- Report
- March 2025
- 150 Pages
Global
From €4403EUR$4,850USD£3,793GBP
- Report
- June 2025
- 144 Pages
Global
From €3586EUR$3,950USD£3,089GBP
- Report
- September 2023
- 143 Pages
Global
From €4039EUR$4,450USD£3,480GBP
- Report
- June 2024
- 270 Pages
Global
From €4534EUR$4,995USD£3,906GBP
- Report
- July 2024
- 156 Pages
Global
From €3858EUR$4,250USD£3,323GBP
- Report
- April 2023
- 80 Pages
South Korea
From €1362EUR$1,500USD£1,173GBP
- Report
- April 2023
- 80 Pages
United States
From €1362EUR$1,500USD£1,173GBP
- Report
- April 2023
- 80 Pages
United Kingdom
From €1362EUR$1,500USD£1,173GBP
From €1362EUR$1,500USD£1,173GBP
- Report
- April 2023
- 80 Pages
Saudi Arabia
From €1362EUR$1,500USD£1,173GBP
- Report
- April 2023
- 80 Pages
Russia
From €1362EUR$1,500USD£1,173GBP
- Report
- April 2023
- 80 Pages
Poland
From €1362EUR$1,500USD£1,173GBP

The Respiratory Disease market within the context of Pulmonary Medicine is a broad field of study that focuses on the diagnosis, treatment, and prevention of diseases that affect the lungs and airways. This includes conditions such as asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, and pulmonary hypertension. Treatment options for these conditions range from lifestyle modifications to medications, and in some cases, surgery. Research in this field is ongoing, with the aim of improving the quality of life for those affected by respiratory diseases.
Companies in the Respiratory Disease market include AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Novartis, and Pfizer. These companies are involved in the development of new treatments and therapies for respiratory diseases, as well as the manufacture and distribution of existing treatments. Show Less Read more